Trekor Metals Limited Common Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Trekor Metals Limited Common Shares trades at $8.99 (market cap $3.03B), while State Street SPDR S&P Biotech ETF trades at $153.91 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.3× Trekor Metals Limited Common Shares's market cap, and Trekor Metals Limited Common Shares is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trekor Metals Limited Common Shares for 0 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TGB | XBI | |
|---|---|---|
Market Cap | $3.03B | $10.11B |
Volume | 3,744,894 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $9.68 | $169.55 |
52-Week Low | $3.75 | $104.99 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $3.43B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →